VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Zhimeng Biopharma's Next-Gen KCNQ2/3 Potassium Channel Opener CB03-154 Receives China IND Approval for Major Depressive Disorder
Zhimeng Biopharma's Next-Gen KCNQ2/3 Potassium Channel Opener CB03-154 Receives China IND Approval for Major Depressive Disorder
Jun 11, 2026 18:27 CST Updated Jun 12, 02:42
Share:
